Early Phase I Study of a 99mTc-Labeled Anti–Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non–Small Cell Lung Cancer

Yan Xing; Gitasha Chand; Changchun Liu; Gary J.R. Cook; Jim O’Doherty; Lingzhou Zhao; Nicholas C.L. Wong; Levente K. Meszaros; Hong Hoi Ting; Jinhua Zhao

doi:10.2967/jnumed.118.224170

Research ArticleOncology

Open Access

Early Phase I Study of a ^99mTc-Labeled Anti–Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non–Small Cell Lung Cancer

Yan Xing, Gitasha Chand, Changchun Liu, Gary J.R. Cook, Jim O’Doherty, Lingzhou Zhao, Nicholas C.L. Wong, Levente K. Meszaros, Hong Hoi Ting and Jinhua Zhao

Journal of Nuclear Medicine September 2019, 60 (9) 1213-1220; DOI: https://doi.org/10.2967/jnumed.118.224170

Yan Xing

1Department of Nuclear Medicine, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of China

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Gitasha Chand

1Department of Nuclear Medicine, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of China

2Nanomab Technology Limited, Shanghai, People’s Republic of China

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Changchun Liu

1Department of Nuclear Medicine, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of China

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Gary J.R. Cook

3Department of Cancer Imaging, School of Biomedical Engineering and Imaging Sciences, King’s College London, London, United Kingdom

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jim O’Doherty

4Department of Molecular Imaging, Sidra Medicine, Doha, Qatar; and

5Weill Cornell Medical College, Education City, Doha, Qatar

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Lingzhou Zhao

1Department of Nuclear Medicine, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of China

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Nicholas C.L. Wong

2Nanomab Technology Limited, Shanghai, People’s Republic of China

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Levente K. Meszaros

2Nanomab Technology Limited, Shanghai, People’s Republic of China

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Hong Hoi Ting

2Nanomab Technology Limited, Shanghai, People’s Republic of China

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jinhua Zhao

1Department of Nuclear Medicine, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of China

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

Data supplements

Supplemental Data

Files in this Data Supplement:

Supplemental Data

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 60, Issue 9

September 1, 2019

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Early Phase I Study of a 99mTc-Labeled Anti–Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non–Small Cell Lung Cancer

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

Early Phase I Study of a ^99mTc-Labeled Anti–Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non–Small Cell Lung Cancer

Yan Xing, Gitasha Chand, Changchun Liu, Gary J.R. Cook, Jim O’Doherty, Lingzhou Zhao, Nicholas C.L. Wong, Levente K. Meszaros, Hong Hoi Ting, Jinhua Zhao

Journal of Nuclear Medicine Sep 2019, 60 (9) 1213-1220; DOI: 10.2967/jnumed.118.224170

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Early Phase I Study of a ^99mTc-Labeled Anti–Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non–Small Cell Lung Cancer

Yan Xing, Gitasha Chand, Changchun Liu, Gary J.R. Cook, Jim O’Doherty, Lingzhou Zhao, Nicholas C.L. Wong, Levente K. Meszaros, Hong Hoi Ting, Jinhua Zhao

Journal of Nuclear Medicine Sep 2019, 60 (9) 1213-1220; DOI: 10.2967/jnumed.118.224170

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

This Month in JNM

PubMed
Google Scholar

Cited By...

Collagen Hybridizing Peptide-Based Radiotracers for Molecular Imaging of Collagen Turnover in Pulmonary Fibrosis
Preclinical development of novel PD-L1 tracers and first-in-human study of [68Ga]Ga-NOTA-RW102 in patients with lung cancers
Non-invasive PD-L1 quantification using [18F]DK222-PET imaging in cancer immunotherapy
Single-Domain Antibody Theranostics on the Horizon
PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell Lung Cancer
First-in-Humans Evaluation of a PD-L1-Binding Peptide PET Radiotracer in Non-Small Cell Lung Cancer Patients
Single-Domain Antibody Nuclear Imaging Allows Noninvasive Quantification of LAG-3 Expression by Tumor-Infiltrating Leukocytes and Predicts Response of Immune Checkpoint Blockade
Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy
Immune Checkpoint Imaging in Oncology: A Game Changer Toward Personalized Immunotherapy?
Imaging Responses to Immunotherapy with Novel PET Tracers

Google Scholar

Oncology

The Evolving Role of FDG-PET/CT in Assessing Primary Cutaneous Lymphoma
Molecular imaging of Renal clear cell carcinoma subtypes as metabolic diseases
Role of PET/CT in the management of multiple myeloma

Show more Oncology

Clinical

The Evolving Role of FDG-PET/CT in Assessing Primary Cutaneous Lymphoma
Molecular imaging of Renal clear cell carcinoma subtypes as metabolic diseases
Role of PET/CT in the management of multiple myeloma

Show more Clinical

Keywords

PD-L1
non–small cell lung cancer
SPECT/CT
Early Phase I
Single domain antibody (sdAb)

Main menu

User menu

Search

Early Phase I Study of a ^99mTc-Labeled Anti–Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non–Small Cell Lung Cancer

Data supplements

Supplemental Data

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Oncology

Clinical

Similar Articles

Keywords